DR. GEORGE OYLER, M.D.
Neurology at Guilford Ave, Baltimore, MD
License number
Maryland D0046921
Category
Neurology
Type
Neurology
Address
Address
2924 Guilford Ave, Baltimore, MD 21218
Phone
(410) 262-3971
Personal information
See more information about GEORGE OYLER at radaris.comName
Address
Phone
2824 Guilford Ave, Baltimore, MD 21218
2924 Guilford Ave, Baltimore, MD 21218
Professional information
Associate Professor Biochemistry, Unl; Founder Synaptic Research Llc; Founder Clean Green Chesapeake Llc
Position:
President and Founder at Synaptic Research LLC, Associate Professor, Biochemistry at University of Nebraska-Lincoln, President and Founder at Clean Green Chesapeake, Research Associate Professor at Johns Hopkins University
Location:
Baltimore, Maryland Area
Industry:
Biotechnology
Work:
Synaptic Research LLC
since Sep 2006
-
President and Founder
University of Nebraska-Lincoln
- Lincoln, Nebraska Area since Sep 2009
-
Associate Professor, Biochemistry
Clean Green Chesapeake
since 2009
-
President and Founder
Johns Hopkins University
- Baltimore Maryland USA since 2006
-
Research Associate Professor
Algal BioEnergy Alliance
2008 - Jun 2012
-
Director
Veritas Labs
Jul 2004 - Sep 2006
-
Director of Therapeutics (Botulinum Biodefense Program)
University of Maryland School of Medicine
Sep 1999 - Jun 2004
-
Assistant Professor of Neurology
Johns Hopkins Hospital
Jun 1998 - Sep 1999
-
Assistant Professor of Neurology
Johns Hopkins Hospital Neurology
Jun 1997 - Jun 1998
-
Instructor of Neurology
Education:
The Johns Hopkins University School of Medicine 1995 - 1997
Post Doc, Neurovirology and Neurodegeneration The Johns Hopkins University School of Medicine 1992 - 1995
Neurology Residency, Neurology Hershey Medical Center, Pennsylvania State University 1984 - 1991
MD, Medicine Hershey Medical Center, Pennsylvania State University 1986 - 1989
PhD, Cell and Molecular Biology Princeton University 1980 - 1984
BSE, Chemical Engineering
Post Doc, Neurovirology and Neurodegeneration The Johns Hopkins University School of Medicine 1992 - 1995
Neurology Residency, Neurology Hershey Medical Center, Pennsylvania State University 1984 - 1991
MD, Medicine Hershey Medical Center, Pennsylvania State University 1986 - 1989
PhD, Cell and Molecular Biology Princeton University 1980 - 1984
BSE, Chemical Engineering
Languages:
Spanish
Designer Ubiquitin Ligases Having A Non-Cleavable Snap25 Domain And E3-Ligase Domain
US Patent:
8343743, Jan 1, 2013
Filed:
Jun 10, 2009
Appl. No.:
12/482420
Inventors:
George A. Oyler - Baltimore MD, US
Yien Che Tsai - Frederick MD, US
Yien Che Tsai - Frederick MD, US
Assignee:
Synaptic Research, LLC - Baltimore MD
International Classification:
C12N 9/00, C12N 1/20, C12N 15/00, C07H 21/04, A61K 38/43
US Classification:
435183, 424 941, 4352523, 4353201, 536 232
Abstract:
The present invention relates to a designer or recombinant ubiquitin ligase molecule that includes a toxin binding domain that is specific for a toxin active fragment, wherein the toxin active fragment is an enzymatically active fragment of one or more toxins or toxin serotypes; and an E3-ligase domain that comprises an E3-ligase or polypeptide that facilitates E2-mediated ubiquitination of the toxin active fragment. In an embodiment, the composition further includes a delivery system that allow the designer ubiquitin ligase to enter the cell. The present invention further includes methods for treating an individual intoxicated with a toxin by administering the designer ubiquitin ligase of the present invention.
Designer Ubiquitin Ligases For Regulation Of Intracellular Pathogenic Proteins
US Patent:
2010027, Nov 4, 2010
Filed:
Jun 10, 2009
Appl. No.:
12/481889
Inventors:
Charles B. Shoemaker - North Grafton MA, US
George A. Oyler - Baltimore MD, US
Saul Tzipori - Shrewsbury MA, US
George A. Oyler - Baltimore MD, US
Saul Tzipori - Shrewsbury MA, US
International Classification:
A61K 39/395, C12N 9/00, C07K 16/18, C07H 21/04, C12N 5/071, C12N 15/79, C07K 14/00, A61P 39/00
US Classification:
4241341, 435183, 5303872, 536 2353, 435325, 4353201, 530324, 530350, 536 231
Abstract:
The present invention relates to a designer or recombinant ubiquitin ligase molecule that includes an antibody fragment that is specific for a toxin active fragment, wherein the toxin active fragment is an enzymatically active fragment of one or more toxins or toxin serotypes; and an E3-ligase domain that comprises an E3-ligase or polypeptide that facilitates E2-mediated ubiquitination of the toxin active fragment. In an embodiment, the composition further includes a delivery system that allow the designer ubiquitin ligase to enter the cell. The present invention further includes methods for treating an individual intoxicated with a toxin by administering the designer ubiquitin ligase of the present invention.
Methods For Identifying Inhibitors Of Botulinum Neurotoxins
US Patent:
8093044, Jan 10, 2012
Filed:
Dec 3, 2009
Appl. No.:
12/630336
Inventors:
Randall Kincaid - Rockville MD, US
George Oyler - Baltimore MD, US
Yien Che Tsai - Frederick MD, US
Paul S. Fishman - Baltimore MD, US
George Oyler - Baltimore MD, US
Yien Che Tsai - Frederick MD, US
Paul S. Fishman - Baltimore MD, US
International Classification:
C07K 14/00, A61K 39/08, C12N 5/10
US Classification:
435325, 530324, 530333, 530350, 530300, 4242391, 435 4, 435 771
Abstract:
A system and method for identifying a botulinum neurotoxin inhibitor employing a botulinum neurotoxin substrate complex having a peptide substrate, preferably SNAP-25, a reporter domain on one side of said peptide substrate and an immobilization domain on the opposite side of said peptide substrate. The botulinum neurotoxin inhibitor is identified by its ability to decrease the relative amount of cleaved complex, detected through measuring a decrease in complex bound to a solid support. The method of the present invention also utilizes novel cells that express a botulinum neurotoxin substrate complex. The methods of the present invention are adapted for cell based screening to monitor the catalytic activity of a BoNT in living cells and to identify molecules that inhibit the catalytic activity of a BoNT in living cells. Also provided are novel stable cell lines that express the botulinum toxin substrate complex and viral vectors capable of efficiently expressing an active light chain of the BoNT within mammalian cells.
Method For Identification Of Protease Activity Inhibitors And Assaying The Presence Of Protease Activity
US Patent:
2011014, Jun 16, 2011
Filed:
Dec 7, 2010
Appl. No.:
12/962610
Inventors:
George Oyler - Baltimore MD, US
Yung-Nien Chang - Elkridge MD, US
Yien Che Tsai - Frederick MD, US
Yung-Nien Chang - Elkridge MD, US
Yien Che Tsai - Frederick MD, US
International Classification:
C12Q 1/68, C12N 15/63
US Classification:
435 618, 435 61, 4353201
Abstract:
A system for the identification of proteases and protease inhibitors is provided. The system has at least two components. The first component is a reporter construct with at least one binding site, a transcriptional promoter, an inducible promoter region, and at least one reporter gene, all functionally connected for expression of the reporter gene(s) in functional coordination with a transcriptional activation agent. The second component is a transcriptional activation agent comprising a nucleic acid binding domain, at least one protease substrate domain, and at least one transcriptional activation domain for an inducible promoter. The system allows detection and evaluation of agents affecting protease activity directed to the protease substrate domain. The system also allows for the detection of the presence of proteases in environmental samples.
Methods For Identifying Inhibitors Of Botulinum Neurotoxins
US Patent:
2006023, Oct 19, 2006
Filed:
Mar 31, 2005
Appl. No.:
11/095055
Inventors:
Randall Kincaid - Rockville MD, US
George Oyler - Baltimore MD, US
Yien Tsai - Baltimore MD, US
Paul Fishman - Baltimore MD, US
George Oyler - Baltimore MD, US
Yien Tsai - Baltimore MD, US
Paul Fishman - Baltimore MD, US
International Classification:
A61K 39/08, G01N 33/554, G01N 33/569, C07K 14/33
US Classification:
424239100, 435007320, 530350000
Abstract:
A system and method for identifying a neurotoxin inhibitor employing a neurotoxin substrate complex having a peptide substrate, preferably SNAP-25, a reporter domain on one side of said peptide substrate and an immobilization domain on the opposite side of said peptide substrate. The neurotoxin inhibitor is identified by its ability to decrease the relative amount of cleaved complex, detected through measuring a decrease in complex bound to a solid support. The method of the present invention also utilizes novel cells that express a neurotoxin substrate complex. The methods of the present invention are adapted for cell based screening to monitor the catalytic activity of a BoNT in living cells and to identify molecules that inhibit the catalytic activity of a BoNT in living cells. Also provided are novel stable cell lines that express the toxin substrate complex and viral vectors capable of efficiently expressing an active light chain of the BoNT within mammalian cells.
Method And Composition For Generating Programmed Cell Death Resistant Algal Cells
US Patent:
2013006, Mar 14, 2013
Filed:
Nov 3, 2010
Appl. No.:
13/505783
Inventors:
Michael J. Betenbaugh - Baltimore MD, US
George A. Oyler - Baltimore MD, US
Julian N. Rosenberg - Naugatuck CT, US
George A. Oyler - Baltimore MD, US
Julian N. Rosenberg - Naugatuck CT, US
Assignee:
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
C12N 1/13, C12N 15/79
US Classification:
435471, 4352572, 4353201
Abstract:
The present invention provides transgenic algal cells resistant to programmed cell death (PCD) and methods and compositions useful in generating such cells. Specifically, the invention utilizes expression of one or more mammalian anti-apoptotic genes in algal cells to promote resistance to PCD, which is useful for stress tolerance and increased cell viability and biomass production during cultivation.
Methods For Identifying Inhibitors Of Botulinum Neurotoxins
US Patent:
2012023, Sep 20, 2012
Filed:
Jan 7, 2012
Appl. No.:
13/345691
Inventors:
Randall L. Kincaid - Rockville MD, US
George Oyler - Baltimore MD, US
Yien Che Tsai - Frederick MD, US
Paul S. Fishman - Baltimore MD, US
George Oyler - Baltimore MD, US
Yien Che Tsai - Frederick MD, US
Paul S. Fishman - Baltimore MD, US
International Classification:
G01N 21/64
US Classification:
435 772
Abstract:
A system and method for identifying a neurotoxin inhibitor employing a neurotoxin substrate complex having a peptide substrate, preferably SNAP-25, a reporter domain on one side of said peptide substrate and an immobilization domain on the opposite side of said peptide substrate. The neurotoxin inhibitor is identified by its ability to decrease the relative amount of cleaved complex, detected through measuring a decrease in complex bound to a solid support. The method of the present invention also utilizes novel cells that express a neurotoxin substrate complex. Also provided are novel stable cell lines that express the toxin substrate complex and viral vectors capable of efficiently expressing an active light chain of the BoNT within mammalian cells.
Methods For The Delivery Of Toxins Or Enzymatically Active Portions Thereof
US Patent:
8492109, Jul 23, 2013
Filed:
Jan 20, 2010
Appl. No.:
12/690427
Inventors:
George A. Oyler - Baltimore MD, US
Charles B. Shoemaker - North Grafton MA, US
Charles B. Shoemaker - North Grafton MA, US
Assignee:
Trustees of Tufts College - Medford MA
International Classification:
C12Q 1/37, C12Q 1/02, C12N 5/07, C12N 15/00
US Classification:
435 24
Abstract:
The present invention relates to methods, systems, and kits for intoxicating cells, neuronal and non-neuronal cells, with a toxin or fragment thereof. This is done by subjecting toxin substrate and a lipid or polymeric carrier (e. g. , DNA uptake facilitating agent) to one or more cells for use in cell based assays. In an aspect, the methods of the present invention allow for high throughput assays and, as such, for the evaluation of drug candidates.
Method For Extraction And Purification Of Oils From Microalgal Biomass Using High-Pressure Co2 As A Solute
US Patent:
2014000, Jan 2, 2014
Filed:
Aug 16, 2011
Appl. No.:
13/816737
Inventors:
Marc D. Donohue - Ellicott City MD, US
Michael J. Betenbaugh - Baltimore MD, US
George A. Oyler - Baltimore MD, US
Julian N. Rosenberg - Naugatuck CT, US
Michael J. Betenbaugh - Baltimore MD, US
George A. Oyler - Baltimore MD, US
Julian N. Rosenberg - Naugatuck CT, US
Assignee:
SYNAPTIC RESEARCH LLC - Baltimore MD
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
C11B 1/10
US Classification:
435410, 554205, 554 8, 435261
Abstract:
The present invention provides methods for the isolation of oils from intact or lysed microorganisms in aqueous media with pressurized carbon dioxide as a solute. Such oils may be used for the production of biofuels. Also provided for are methods for harvesting and rupturing whole cell microorganisms in aqueous media with pressurized carbon dioxide as a solute